Following a full submission:
pazopanib (Votrient®) is not recommended for use within NHS Scotland.
Indication under review: For the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes.
In a pivotal study, pazopanib significantly improved progression-free survival compared with placebo in adult patients with selective subtypes of advanced STS. However there was no significant improvement in overall survival.
The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient to gain acceptance by SMC, and in addition the submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice163KB (PDF)
Medicine details
- Medicine name:
- pazopanib (Votrient)
- SMC ID:
- 820/12
- Indication:
- For the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 December 2012